Supplementary Table 5. Inflammatory biomarker levels by group during the study period

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Group 1 (n=41)</th>
<th>Group 2 (n=54)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Days 1–2</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-6 (pg/ml)</td>
<td>190.7±222.7</td>
<td>558.6±1664.5</td>
<td>0.001</td>
</tr>
<tr>
<td>TNF-α (pg/ml)</td>
<td>31.3±52.0</td>
<td>37.1±32.4</td>
<td>0.01</td>
</tr>
<tr>
<td>IL-10 (pg/ml)</td>
<td>101.1±214.6</td>
<td>130.6±194.8</td>
<td>0.001</td>
</tr>
<tr>
<td>IL-10/TNF-α</td>
<td>2.1 (0.8–3.8)</td>
<td>2.3 (1.3–4.5)</td>
<td>0.3</td>
</tr>
<tr>
<td><strong>Days 3–4</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-6 (pg/ml)</td>
<td>173.5±218.3</td>
<td>90.6±152.3</td>
<td>0.16</td>
</tr>
<tr>
<td>TNF-α (pg/ml)</td>
<td>30.1±51.1</td>
<td>14.7±11.9</td>
<td>0.44</td>
</tr>
<tr>
<td>IL-10 (pg/ml)</td>
<td>114.7±233.8</td>
<td>28.4±33.3</td>
<td>0.11</td>
</tr>
<tr>
<td>IL-10/TNF-α</td>
<td>2.0 (1.0–4.4)</td>
<td>1.6 (0.8–2.8)</td>
<td>0.61</td>
</tr>
<tr>
<td><strong>Days 6–8</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-6 (pg/ml)</td>
<td>192.2±225.7</td>
<td>71.6±134.8</td>
<td>0.004</td>
</tr>
<tr>
<td>TNF-α (pg/ml)</td>
<td>35.4±53.5</td>
<td>13.5±12.5</td>
<td>0.03</td>
</tr>
<tr>
<td>IL-10 (pg/ml)</td>
<td>124.1±232.3</td>
<td>25.1±38.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IL-10/TNF-α</td>
<td>2.2 (1.1–5.7)</td>
<td>1.3 (0.8–2.7)</td>
<td>0.03</td>
</tr>
</tbody>
</table>

Values are presented as mean±standard deviation or median (interquartile range).
IL: interleukin; TNF: tumor necrosis factor.